Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Moderna Inc (MRNA)

723 + Investors. Track Smart Money conviction in MRNA. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +51
Streak
2Q ▲
Buyers last Q
55%

Smart Money Signals — MRNA

Based on 730 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 2 quarters in a row

last 6Q
For 2 consecutive quarters, more hedge funds added MRNA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
📊

High ownership — 78% of 3.0Y peak

78% of all-time peak
730 funds currently hold this stock — 78% of the 3.0-year high of 932 funds (reached 2024 Q2). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
📶

Steady growth — +8% more funds vs a year ago

fund count last 6Q
+51 new funds entered over the past year (+8% YoY). Gradual, steady growth in institutional ownership is generally a healthy signal — not a speculative rush, but consistent conviction.
🟡

Slight buying edge — 55% buying

402 buying324 selling
Last quarter: 402 funds bought or added vs 324 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+29 vs last Q)

new funds entering per quarter
Funds opening a new MRNA position: 94 → 74 → 125 → 154. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

62% of holders stayed for 2+ years

■ 62% conviction (2yr+) ■ 18% medium ■ 20% new
452 out of 730 hedge funds have held MRNA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
💰

Price up while funds trimmed (+62% value, -4% shares)

Value
+61%
Shares
-4%
Last quarter: total value of institutional MRNA holdings rose +62% even though funds reduced share count by 4%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.
🚀

Acceleration phase — new buyers rushing in

94 → 94 → 74 → 125 → 154 new funds/Q
New funds entering each quarter: 94 → 74 → 125 → 154. The pace of institutional discovery is accelerating sharply. This is the 'hot idea' phase — the thesis is being passed from fund to fund. You are not late — the accumulation wave is still building.
🏛️

Veteran-anchored — 68% veterans vs 20% newcomers

■ 68% veterans ■ 11% 1-2yr ■ 20% new
Entry-cohort mix of 790 holders: 540 (68%) are 2+ year veterans, 89 entered 1–2 years ago, and 161 (20%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
🏆

Elite ownership — 55% AUM from top-100 funds

55% from top-100 AUM funds
57 of 715 holders are among the 100 largest funds by AUM, controlling 55% of total institutional value in MRNA. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.
2.5
out of 10
Low Exit Risk
Exit risk score 2.5/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — MRNA

In 2026 Q1, 402 hedge funds were net buyers of MRNA (154 opened a new position, 248 added to an existing one), while 324 reduced or exited (221 trimmed, 103 sold completely) — a 55% buyer ratio, indicating a slight buying edge. Net buying has persisted for two consecutive quarters, a positive momentum signal. 55% of total institutional value in MRNA is held by top-100 AUM funds, reflecting elite-tier ownership quality. Net fund flow last quarter: +51 funds (more new holders than closures). Total institutional holders: 730.

Hedge Fund Ownership: MRNA

How many hedge funds hold MRNA — quarterly history vs. share price
Quarterly hedge fund ownership of MRNA vs. share price

Market Analysis: MRNA

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: MRNA

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Moderna Inc (MRNA) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much MRNA has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 75d ago
MRNA
-1.8%
XLV
+4.9%

MRNA outperformed XLV by -6.7% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 30d ago
MRNA
+1.8%
XLV
+6.0%

Since the filing became public, MRNA outperformed XLV by -4.2% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Broad Consensus, Selective Conviction

Many quality funds hold this stock, but top-tier positions remain relatively small.

48 top-rated funds 4 high-conviction
Consensus
7.3
/ 10
breadth
×
Elite
4.0
/ 10
conviction
Hedge Fund Positioning: MRNA
723 + Investors

Track Smart Money conviction in MRNA. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 723 679 6.48%
13F Shares 374M 390M -3.99%
Total Value $18.70B $11.55B 61.92%
New Positions 152 125 +27
Increased Positions 227 170 +57
Closed Positions 108 74 +34
Reduced Positions 208 245 -37
Total Calls 34 36 -5.56%
Total Puts 41 38 7.89%
PUT/CALL Ratio 1.21 1.06 Bearish

Statistics: MRNA

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

723 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in MRNA. Verified SEC 13F-HR filings.

QUARTER:
Top 25 MRNA holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Merck & Co., Inc. 33.56% 2,308,190 $117.3M
2 Theleme Partners LLP 27.24% 8,048,245 $408.9M
3 Flagship Pioneering, LLC 20.26% 4,632,149 $235.3M
4 Step Capital Management Pte. Ltd. 13.15% 645,000 $32.8M
5 Mount Capital Ltd 8.09% 395,200 $20.1M
6 Plustick Management LLC 5.40% 220,000 $11.2M
7 Telemark Asset Management, LLC 2.35% 500,000 $25.4M
8 Affinity Asset Advisors, LLC 2.10% 800,000 $40.6M
9 Artia Global Partners LP 2.03% 200,000 $10.2M
10 Green Alpha Advisors, LLC 1.72% 34,338 $1.7M
11 Collar Capital Management, LLC 1.63% 49,686 $2.5M
12 Crawford Fund Management, LLC 1.55% 158,200 $8.0M
13 Chapin Davis, INC. 1.42% 125,539 $6.4M
14 Diadema Partners LP 1.38% 159,400 $8.1M
15 Aufman Associates Inc 1.35% 56,998 $2.7M
16 DC Investments Management, LLC 1.33% 68,624 $3.5M
17 Legal Advantage Investments, Inc. 1.26% 48,175 $2.4M
18 Twin Focus Capital Partners, LLC 1.08% 185,601 $9.4M
19 Baillie Gifford & Co 1.04% 19,985,876 $1.02B
20 Quantessence Capital LLC 1.01% 4,063 $206K
21 Perceptive Advisors LLC 0.99% 1,000,000 $50.8M
22 Banque Pictet & Cie SA 0.98% 2,748,754 $139.6M
23 Douglas Lane & Associates, LLC 0.96% 1,311,480 $66.6M
24 Hamilton Wealth, LLC 0.87% 242,184 $12.3M
25 Two Seas Capital LP 0.78% 1,100,000 $55.9M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Moderna Inc (MRNA)

What does the Smart Money Trend signal show for MRNA?

Buying streak — 2 quarters in a row: For 2 consecutive quarters, more hedge funds added MRNA than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for MRNA?

Slight buying edge — 55% buying: Last quarter: 402 funds bought or added vs 324 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for MRNA holders?

Elite ownership — 55% AUM from top-100 funds: 57 of 715 holders are among the 100 largest funds by AUM, controlling 55% of total institutional value in MRNA. When the biggest players dominate the cap table, it signifies deep institutional support — since mega-funds deploy the most rigorous due diligence and capital.

How long have hedge funds held MRNA?

62% of holders stayed for 2+ years: 452 out of 730 hedge funds have held MRNA for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Moderna Inc (MRNA) following the 2026 Q1 hedge fund 13F filings?

As of today, MRNA has moved +1.8% since the 2026 Q1 13F filing date (May 15, 2026), compared to +6.0% for the XLV sector ETF — an outperformance of -4.2%. Since the quarter end (March 31, 2026), MRNA has gained -1.8% vs +4.9% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →